You might have come across PT-141 online as a peptide that can increase sex drive or help with erections. Some websites promote it as an alternative to medicines such as Viagra, while others claim it can improve sexual performance. But what does the evidence actually show? Here’s what we know about PT-141, its potential side effects and its legal status in Australia.
What is PT-141?
PT-141, also known as bremelanotide, is a synthetic peptide. Peptides are short chains of amino acids, which are the building blocks of proteins. PT-141 acts on receptors in the brain called melanocortin receptors, which are involved in several bodily functions, including sexual responses. This makes it different from erectile dysfunction medicines such as sildenafil (Viagra) and tadalafil (Cialis), which help improve blood flow to the penis.
Although PT-141 has been investigated as a treatment for both erectile dysfunction and low sex drive, these are different problems. A treatment that helps someone get an erection doesn’t necessarily increase their interest in sex.
Does PT-141 work for erectile dysfunction?
Early research suggested PT-141 could help some men achieve erections. A 2004 clinical trial found that PT-141 produced measurable erectile responses in men compared with a placebo. A later study involving men who hadn’t responded to sildenafil also reported improvements in erectile function and sexual satisfaction, although side effects were more common among men receiving PT-141. These findings were promising, but they weren’t enough to establish PT-141 as a safe and effective treatment for erectile dysfunction.
PT-141 was originally developed as a nasal spray. During its development, researchers identified increases in blood pressure, raising concerns about cardiovascular safety. The US Food and Drug Administration (FDA) questioned whether the benefits were sufficient to justify the risks. In 2007, the companies developing the drug announced that plans for larger trials in men would be delayed.
Development subsequently shifted to an injectable formulation, which provided more predictable absorption. However, this didn’t eliminate the drug’s effects on blood pressure. The later approval program focused on women with a particular sexual desire disorder rather than erectile dysfunction in men.
Can PT-141 increase sex drive in men?
PT-141 affects signalling pathways in the brain involved in sexual responses, which has led to interest in whether it could increase sexual desire, but most research involving men has focused on erectile function.
There isn’t enough good-quality evidence to establish PT-141 as an effective treatment for low sexual desire in men. Low sex drive can have many contributing factors, including stress, relationship difficulties, medication effects, poor sleep, mental health concerns and hormonal conditions. Understanding what’s contributing to a change in sexual desire is important because different causes may need different approaches
Is PT-141 approved for sexual problems?
In 2019, the US FDA approved injectable bremelanotide under the brand name Vyleesi for certain premenopausal women with acquired, generalised hypoactive sexual desire disorder. This is a condition involving persistently low sexual desire that causes significant distress and isn’t explained by other factors.
According to the FDA-approved prescribing information, Vyleesi is not indicated for men or to improve sexual performance.
Approval for a particular condition in women doesn’t establish that PT-141 is effective or safe for treating sexual problems in men.
Vyleesi is not approved by the Australian Therapeutic Goods Administration (TGA).
What about combining PT-141 with Viagra?
Researchers have also investigated combining PT-141 with sildenafil. An early clinical trial involving 19 men found improved erectile responses compared with sildenafil alone. More recently, researchers have begun investigating the combination in men who don’t respond adequately to PDE5 inhibitors.
However, this remains an experimental approach. There isn’t enough established clinical evidence to recommend the combination as a treatment for erectile dysfunction.
What are the risks and side effects of PT-141?
PT-141 can cause side effects, and its effects on blood pressure are particularly important.
Reported side effects include:
The US prescribing information for Vyleesi states that it must not be used by people with uncontrolled high blood pressure or known cardiovascular disease.
Most of the detailed safety information for the approved injectable formulation comes from studies involving women. The frequency of these side effects cannot automatically be assumed to be the same in men or with unapproved formulations.
There are additional risks associated with purchasing PT-141 from unregulated suppliers. Products sold online may not contain what their labels claim, and their quality, strength and sterility may be uncertain.
Is PT-141 legal in Australia?
PT-141 is not an established TGA-approved treatment for erectile dysfunction or low sexual desire in men. In Australia, therapeutic peptides are regulated by the Therapeutic Goods Administration (TGA). Medicines generally need to be included in the Australian Register of Therapeutic Goods (ARTG) before they can be supplied, although limited exceptions apply.
The TGA explains how therapeutic peptides are regulated, including restrictions on importing, supplying and advertising unapproved products. . Products that haven’t been assessed by the TGA for safety, quality and effectiveness may carry significant risks. Importantly, a product being advertised online doesn’t mean it’s approved or lawful to obtain in Australia. Labels such as ‘research use only’ don’t remove regulatory requirements.
The TGA also warns against buying unapproved peptide products online, particularly products from unknown or unregulated sources.
What should you do if you’re having problems with erections or sex drive?
If you’re having trouble getting or maintaining an erection, or you’ve noticed a change in your sex drive, speak with your GP.
Erectile dysfunction can be related to blood vessel health, diabetes, medication effects, psychological factors and other conditions. It is often an early sign of cardiovascular disease.
There are established treatments for erectile dysfunction, including PDE5 inhibitors, psychological support and other options depending on the cause.
Low sex drive may need a different approach because having less interest in sex isn’t the same as having difficulty getting an erection.
PT-141 showed some promising effects in early research, but research did not result in it being established as a safe and effective treatment for sexual problems in men. Its potential benefits need to be considered alongside its cardiovascular risks and the limited evidence supporting its use.












